AXL and enolase 2 associate with therapy resistance to tyrosine kinase inhibitors lenvatinib and cabozantinib in renal cancer cells

Journal of Proteomics · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles